The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-11-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/8/352 |
id |
doaj-1156cf77efd04e84a56aba3284a8f5a2 |
---|---|
record_format |
Article |
spelling |
doaj-1156cf77efd04e84a56aba3284a8f5a22020-11-24T23:27:17ZengBMCBMC Cancer1471-24072008-11-018135210.1186/1471-2407-8-352The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancerMiller Andrew FBeck Adam WSullivan Laura ADineen Sean PCarbon Juliet GMamluk RoniWong HenryBrekken Rolf A<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascular endothelial growth factor (VEGF) is a well-characterized mediator of tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2). In this study, we evaluate the use of CT-322, a novel biologic (Adnectin). This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2.</p> <p>Methods</p> <p>The efficacy of CT-322 was evaluated <it>in vivo </it>using two orthotopic pancreatic tumor models. The first model was a human tumor xenograft where MiaPaCa-2 cells were injected into the tail of the pancreas of nude mice. The second model was a syngeneic tumor using Pan02 cells injected into pancreas of C57BL/6J mice. In both models, therapy was initiated once primary tumors were established. Mice bearing MiaPaCa-2 tumors were treated with vehicle or CT-322 alone. Gemcitabine alone or in combination with CT-322 was added to the treatment regimen of mice bearing Pan02 tumors. Therapy was given twice a week for six weeks, after which the animals were sacrificed and evaluated (grossly and histologically) for primary and metastatic tumor burden. Primary tumors were also evaluated by immunohistochemistry for the level of apoptosis (TUNEL), microvessel density (MECA-32), and VEGF-activated blood vessels (Gv39M).</p> <p>Results</p> <p>Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft and syngeneic models of pancreatic cancer. Additionally, CT-322 treatment increased apoptosis, reduced microvessel density and reduced the number of VEGF-activated blood vessels in tumors. Finally, CT-322, in combination with gemcitabine was safe and effective at controlling the growth of syngeneic pancreatic tumors in immunocompetent mice.</p> <p>Conclusion</p> <p>We conclude that CT-322 is an effective anti-VEGFR2 agent and that further investigation of CT-322 for the treatment of pancreatic cancer is warranted.</p> http://www.biomedcentral.com/1471-2407/8/352 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Miller Andrew F Beck Adam W Sullivan Laura A Dineen Sean P Carbon Juliet G Mamluk Roni Wong Henry Brekken Rolf A |
spellingShingle |
Miller Andrew F Beck Adam W Sullivan Laura A Dineen Sean P Carbon Juliet G Mamluk Roni Wong Henry Brekken Rolf A The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer BMC Cancer |
author_facet |
Miller Andrew F Beck Adam W Sullivan Laura A Dineen Sean P Carbon Juliet G Mamluk Roni Wong Henry Brekken Rolf A |
author_sort |
Miller Andrew F |
title |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
title_short |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
title_full |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
title_fullStr |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
title_full_unstemmed |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
title_sort |
adnectin ct-322 is a novel vegf receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2008-11-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascular endothelial growth factor (VEGF) is a well-characterized mediator of tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2). In this study, we evaluate the use of CT-322, a novel biologic (Adnectin). This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2.</p> <p>Methods</p> <p>The efficacy of CT-322 was evaluated <it>in vivo </it>using two orthotopic pancreatic tumor models. The first model was a human tumor xenograft where MiaPaCa-2 cells were injected into the tail of the pancreas of nude mice. The second model was a syngeneic tumor using Pan02 cells injected into pancreas of C57BL/6J mice. In both models, therapy was initiated once primary tumors were established. Mice bearing MiaPaCa-2 tumors were treated with vehicle or CT-322 alone. Gemcitabine alone or in combination with CT-322 was added to the treatment regimen of mice bearing Pan02 tumors. Therapy was given twice a week for six weeks, after which the animals were sacrificed and evaluated (grossly and histologically) for primary and metastatic tumor burden. Primary tumors were also evaluated by immunohistochemistry for the level of apoptosis (TUNEL), microvessel density (MECA-32), and VEGF-activated blood vessels (Gv39M).</p> <p>Results</p> <p>Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft and syngeneic models of pancreatic cancer. Additionally, CT-322 treatment increased apoptosis, reduced microvessel density and reduced the number of VEGF-activated blood vessels in tumors. Finally, CT-322, in combination with gemcitabine was safe and effective at controlling the growth of syngeneic pancreatic tumors in immunocompetent mice.</p> <p>Conclusion</p> <p>We conclude that CT-322 is an effective anti-VEGFR2 agent and that further investigation of CT-322 for the treatment of pancreatic cancer is warranted.</p> |
url |
http://www.biomedcentral.com/1471-2407/8/352 |
work_keys_str_mv |
AT millerandrewf theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT beckadamw theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT sullivanlauraa theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT dineenseanp theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT carbonjulietg theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT mamlukroni theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT wonghenry theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT brekkenrolfa theadnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT millerandrewf adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT beckadamw adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT sullivanlauraa adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT dineenseanp adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT carbonjulietg adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT mamlukroni adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT wonghenry adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer AT brekkenrolfa adnectinct322isanovelvegfreceptor2inhibitorthatdecreasestumorburdeninanorthotopicmousemodelofpancreaticcancer |
_version_ |
1725552597234876416 |